Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,237 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06786624RecruitingPhase 3
Testing a new drug for depression that hasn't fully responded to treatment
This trial tests a new medication called NBI-1065845 added to your current antidepressant for people with depression that hasn't fully responded to treatment. It aims to see if this combination can better improve your symptoms.
Little Rock, ArkansasAges 18 years+ - NCT06786676RecruitingPhase 1
Safety study of AS-S603 in healthy volunteers
This trial tests a new drug called AS-S603 in healthy volunteers to see if it is safe and how the body processes it. It is an early-phase study for people of Korean or Caucasian background.
SeoulAges 19–85 - NCT06787144RecruitingPhase 1
Studying ELVN-001 for Japanese adults with CML
This trial tests a new drug called ELVN-001 for people with chronic myeloid leukemia (CML) who have not responded to or could not take at least two prior treatments. It's for Japanese patients, including those with a specific genetic change (T315I mutation). The goal is to see if ELVN-001 can help control the leukemia.
Akita, AkitaAges 18 years+ - NCT06793709Recruiting
Study of Tasfygo for bile duct cancer with FGFR2 gene change
This study is watching people with a certain type of bile duct cancer that has a specific gene change (FGFR2 fusion). It looks at what happens when they take the drug Tasfygo after their cancer did not respond to chemotherapy.
TokyoAges Any age - NCT06796686RecruitingPhase 1
HIV vaccine safety and immune response study for healthy adults
This trial tests a new two-part HIV vaccine regimen in healthy adults without HIV. The goal is to see if it is safe and produces an immune response that could help prevent HIV.
San Francisco, CaliforniaAges 18–55 - NCT06797635RecruitingPhase 2
Study of Patritumab Deruxtecan and Pembrolizumab for High-Risk Early Breast Cancer
This trial tests a combination of targeted therapies (patritumab deruxtecan plus pembrolizumab) along with other anticancer drugs for people with a high-risk type of early-stage breast cancer that is either triple-negative or has very low hormone receptors and is HER2-negative. The goal is to see if this approach can help prevent the cancer from coming back.
Santa Monica, CaliforniaAges 18 years+ - NCT06800651RecruitingPhase 2
A new drug for fast-growing polycystic kidney disease
This trial tests a drug (JMKX003142) for people with autosomal dominant polycystic kidney disease that is getting worse quickly. It may help slow down kidney damage.
Beijing, Beijing MunicipalityAges 18–55 - NCT06800963RecruitingPhase 1/Phase 2
A new BCG treatment for bladder cancer that hasn't spread
This trial tests a new form of intravesical (given directly into the bladder) treatment called rMBCG for people with non-muscle invasive bladder cancer who have not had BCG therapy before. It may be an option for those with certain types of early bladder cancer, including carcinoma in situ (CIS) or papillary tumors after removal surgery.
Chandler, ArizonaAges 18–85 - NCT06803706Recruiting
Gut bacteria changes during smoking quit attempt
This study looks at how quitting smoking changes your body's gut bacteria and metabolism. It is for people with a substance use disorder who want to stop smoking.
FehringAges 18 years+ - NCT06805695Recruiting
Long-term follow-up for iECURE trial participants
This study follows up with people who took part in an earlier iECURE trial (such as a gene therapy study) to check on their health over time. It collects information to see how safe and lasting the treatment effects are.
LondonAges 7 months–1.3 years - NCT06806033RecruitingPhase 2
New drug combo for relapsed aggressive B-cell lymphoma
This trial tests a new combination of drugs (glofitamab plus gemcitabine and oxaliplatin) for people with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The goal is to see if this approach can improve outcomes while managing side effects.
Anchorage, AlaskaAges 18 years+ - NCT06810505RecruitingPhase 3
Oral atogepant for preventing migraines in teens
This trial tests an oral medication called atogepant to see if it can prevent migraines in teens aged 12–17. It aims to reduce how often migraines happen and track any side effects.
Huntsville, AlabamaAges 12–17 - NCT06810960Recruiting
Leqembi use in South Korean Alzheimer's patients
This study follows people with Alzheimer's who are already taking Leqembi (lecanemab) after being in the JOY-ALZ study. It collects medical information to check how the treatment works in real-world use.
Nutley, New JerseyAges 19 years+ - NCT06813911RecruitingPhase 3
Testing pelacarsen for high Lp(a) in heart disease patients
This trial tests a new medicine called pelacarsen for people with very high Lp(a) (a type of cholesterol) and existing heart or blood vessel disease. It aims to see if adding pelacarsen to your current cholesterol treatment can lower your Lp(a) levels further.
Birmingham, AlabamaAges 18–80 - NCT06815380Recruiting
Study on lebrikizumab for people with atopic dermatitis
This study looks at how lebrikizumab (Ebglyss) affects daily life and skin symptoms in adults with moderate-to-severe eczema. You may join if your doctor has prescribed this medication as part of your regular care.
Aarhus, DenmarkAges 18 years+ - NCT06816147Recruiting
HealthyW8: a weight-health study for adults 60+
This study tests a program to help people aged 60 and older in Luxembourg maintain a healthy weight using a smartphone app. It may be a good fit if you are generally healthy, not on a strict diet, and want to prevent weight gain as you age.
LuxembourgAges 60 years+ - NCT06824103RecruitingPhase 4
Study of ruxolitinib for chronic graft-versus-host disease in China
This trial tests if ruxolitinib can help people with chronic graft-versus-host disease (cGvHD) that hasn't improved with steroids. It's for Chinese patients aged 12 and older who have moderate to severe cGvHD after a stem cell transplant.
Hefei, AnhuiAges 12–100 - NCT06826612RecruitingPhase 1/Phase 2
Gene therapy trial for early Huntington's disease
This trial tests a gene therapy called SPK-10001 for people with early-stage Huntington's disease. It aims to slow the progression of symptoms by targeting the genetic cause of the disease.
Boston, MassachusettsAges 25–65 - NCT06827366Recruiting
Lifestyle study for people at high risk of colorectal cancer
This study tests a lifestyle program for people who are at high risk for colorectal cancer but have not been diagnosed. The goal is to see if healthy changes can help lower your risk over one year.
Lyon, FranceAges 35–74 - NCT06830343RecruitingPhase 1
Safety study of SYH9017 for overweight and obesity
This study tests a new medication called SYH9017 for people who are overweight or have obesity. It aims to see how safe the drug is, how well it is tolerated, and how the body processes it. Participants will receive either the drug or a placebo and be monitored closely.
Beijing, Beijing MunicipalityAges 18–60 - NCT06830759Recruiting
Real-world study of epcoritamab for lymphoma
This study looks at how well epcoritamab works for people with diffuse large B-cell lymphoma or follicular lymphoma who have already tried two or more treatments. Researchers want to see how it works in routine care, not in a strict research setting.
Ciudad Autonoma de Buenos Aire, Buenos AiresAges 18 years+ - NCT06831539RecruitingPhase 1
How bowel prep affects gut bacteria recovery
This study looks at how the bowel preparation medicine (PEG) used before a colonoscopy affects the bacteria living in your gut and how well they recover afterward. Healthy volunteers will take the bowel prep and provide stool samples to help researchers understand this process.
Montreal, QuebecAges 18–70 - NCT06832410RecruitingPhase 3
Testing VX-880 for type 1 diabetes with a kidney transplant
This trial tests a new treatment called VX-880 for people who have had type 1 diabetes for at least 5 years and have already received a kidney transplant. The goal is to see if VX-880 can improve blood sugar control while you continue your current transplant medications.
Philadelphia, PennsylvaniaAges 18–65 - NCT06838845Recruiting
A study on upadacitinib for Chinese adults with moderate to severe ulcerative colitis
This study is looking at how well the drug upadacitinib works and how safe it is for Chinese adults with moderate to severe ulcerative colitis. It is not a treatment trial, but will observe patients who are already taking upadacitinib as decided by their doctor.
Guangzhou, GuangdongAges 18 years+
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,237 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.